Generali Investments CEE investicni spolecnost a.s. Decreases Stock Holdings in Amgen Inc. $AMGN

Key Points

• Generali Investments CEE has decreased its stock holdings in Amgen Inc. by 15.9%, owning 11,920 shares valued at approximately $3.3 million after selling 2,250 shares.
• Institutional investors have been active, with Alley Investment Management increasing its holdings by 1.1% and Union Bancaire Privee boosting theirs by 94.4% in the same quarter.
• Analysts maintain a consensus "Hold" rating for Amgen, with target prices ranging from $261 to $326, reflecting varied confidence in the company's future performance.

Generali Investments CEE investicni spolecnost a.s. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,920 shares of the medical research company's stock after selling 2,250 shares during the period. Generali Investments CEE investicni spolecnost a.s.'s holdings in Amgen were worth $3,328,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Alley Investment Management Company LLC boosted its holdings in shares of Amgen by 1.1% in the 2nd quarter. Alley Investment Management Company LLC now owns 25,052 shares of the medical research company's stock valued at $6,995,000 after buying an additional 280 shares in the last quarter. Union Bancaire Privee UBP SA boosted its holdings in shares of Amgen by 94.4% in the 2nd quarter. Union Bancaire Privee UBP SA now owns 4,432 shares of the medical research company's stock valued at $1,237,000 after buying an additional 2,152 shares in the last quarter. Emerald Advisors LLC boosted its holdings in shares of Amgen by 18.2% in the 2nd quarter. Emerald Advisors LLC now owns 4,291 shares of the medical research company's stock valued at $1,198,000 after buying an additional 662 shares in the last quarter. Park Place Capital Corp boosted its holdings in shares of Amgen by 7.0% in the 2nd quarter. Park Place Capital Corp now owns 2,064 shares of the medical research company's stock valued at $600,000 after buying an additional 135 shares in the last quarter. Finally, XML Financial LLC boosted its holdings in shares of Amgen by 0.7% in the 2nd quarter. XML Financial LLC now owns 22,269 shares of the medical research company's stock valued at $6,218,000 after buying an additional 154 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Amgen from $310.00 to $315.00 and gave the company a "neutral" rating in a report on Wednesday, September 24th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. UBS Group lowered their target price on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday, August 6th. Bank of America upped their price target on shares of Amgen from $261.00 to $272.00 and gave the company an "underperform" rating in a research report on Friday, September 26th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $309.70.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.69% of the stock is owned by insiders.

Amgen Stock Performance

Shares of Amgen stock opened at $282.20 on Wednesday. The business's fifty day simple moving average is $287.95 and its 200 day simple moving average is $288.57. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The firm has a market capitalization of $151.93 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.38 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business's revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date was Friday, August 22nd. Amgen's payout ratio is presently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.